AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01265303 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prolonged telemetric Full Disclosure ECG recording.
Description: Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
Study NCT01509911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-118
Description: TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
Study NCT01509911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Monthly cycles of 3 weekly treatments a month and one week off of treatment
Study NCT02982291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Williams flexion protocol
Description: The Williams flexion protocol group will participate in 15 treatment sessions.
Study NCT02982291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focused spinal stenosis rehabilitation
Description: The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
Study NCT00946920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
Study NCT00946920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin acetate
Description: The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
Study NCT04392895 — intervention group
Intervention type: PROCEDURE
Intervention: Para Aortic Lymphadenectomy (PAL) by laparoscopy
Description: Para Aortic Lymphadenectomy (PAL) by laparoscopy
Study NCT04097340 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Retraining (ABR)
Description: Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
Study NCT04097340 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Training
Description: Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
Study NCT02461160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915 suspension
Description: TAK-915 oral suspension
Study NCT02122224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber breakfast
Description: Breakfast will contain 10-11g fiber.
Study NCT02122224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Breakfast
Description: Breakfast will contain 19-20g of protein.
Study NCT02122224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein/High Fiber Breakfast
Description: Breakfast will include 19-22g of protein and 10-12g of fiber.
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60 mg/m2 IV every 21 days for cycles 1-4
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 60 mg/m2 IV every 21 days for cycles 1-4
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for cycles 1-4
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2 IV every 21 days for cycles 1-4
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
Study NCT00486668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
Study NCT03633812 — intervention group
Intervention type: OTHER
Intervention: Observational study, Beta blocker medication history
Description: Observational study, Beta blocker medication history
Study NCT00637962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV glycoprotein CN54gp140 (vaccine)
Description: vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
Study NCT00637962 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Carbopol 974
Description: vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
Study NCT03614299 — intervention group
Intervention type: OTHER
Intervention: Ecological symptom measurements using a webapp
Description: A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
Study NCT03614299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interferometry
Description: Evaluation of the mebomian function using the LipiView methodology
Study NCT02053961 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: 1Hz dTMS real treatment
Study NCT02053961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: 1Hz dTMS real treatment
Study NCT02053961 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: 1Hz dTMS SHAM treatment
Study NCT00326443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 909
Description: 5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
Study NCT00326443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffer placebo administered on Day 0.
Study NCT00326443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi Polysaccharide
Description: 25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
Study NCT00326443 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vi Polysaccharide
Description: 25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
Study NCT00056030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT02514148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic patient education
Description: Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
Study NCT02514148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
Study NCT02514148 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
Study NCT02514148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
Study NCT01850355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
Study NCT03504631 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT01105598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (ascending dose), daily for 14 days
Study NCT01105598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (optimized dose), daily for 28 days
Study NCT01105598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002 or placebo
Description: ETC-1002 (20 mg), daily for 14 days
Study NCT02572622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non -surgical spinal decompression therapy
Description: it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
Study NCT02572622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction massage,
Description: deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
Study NCT02572622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrotherapy
Description: electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
Study NCT00056030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00056030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00056030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02572622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: special lumbar stabilization exercises were applied in advanced protocol.
Study NCT03202264 — intervention group
Intervention type: OTHER
Intervention: TAPER
Description: The intervention is medication reduction. This arm is comprised of:~* Medication reconciliation~* Identification of patient priorities for care~* Identification of medications that are potentially appropriate for discontinuation/dose reduction~* Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~* Identification of medications for trial of discontinuation/dose reduction (shared decision making)~* Pause of medication and clinical monitoring
Study NCT03025061 — intervention group
Intervention type: OTHER
Intervention: Assessment of E-nose measurements
Description: Breath sampling through E-nose pneumopipe
Study NCT03929848 — intervention group
Intervention type: PROCEDURE
Intervention: Cuff pressure
Description: observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
Study NCT05812521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block with methylene blue
Description: The paravertebral space is identified under ultrasound guidance and after negative aspiration a 3 ml test dose of anesthetic is injected. After observing widening of the paravertebral space and anterior pleural displacement to confirm the correct needle positioning, a bolus dose of 20 mL 0.5% ropivacaine with a solution of 1 ml 1% methylene blue and 4 ml of saline will be injected in the paravertebral space. At the start of the surgery, the spread of the solution of anesthetic and methylene blue will be assessed through visualization in thoracoscopy and if necessary the block will be repeated. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
Study NCT00774605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline free base solution
Description: A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
Study NCT00774605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline free base patch
Description: A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
Study NCT05812521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Anesthesia
Description: The epidural catheter will be placed using the loss of resistance technique, and after ruling out intravenous or intrathecal catheter placement with a negative aspiration test dose, an initial dose of 10 mL 0.25% bupivacaine will be injected. Continuous infusion will be started with with 0.125 % bupivacaine + fentanyl 0.5 mcg/ ml at 6-10 ml/hour will be started based on the patient weight for 48 hours postoperatively. After the surgery, intravenous acetaminophen will be administered 3 times daily and tramadol 50 mg will be prescribed as rescue analgesic.
Study NCT02984033 — intervention group
Intervention type: RADIATION
Intervention: Head and Neck patients
Description: Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
Study NCT02410109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCRIPT integrated model
Description: Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
Study NCT02384122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Two injections of 20 mg will be given monthly.
Study NCT02313194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulation
Description: Determine if epidural stimulation can improve motor function
Study NCT02313194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Determine if the pharmacological agent in combination with the stimulator can improve motor function.
Study NCT03139045 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Venous puncture in elderly patients
Description: Venous puncture in elderly patients
Study NCT02256826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS
Study NCT02256826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: NORVIR®
Study NCT02256826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra®
Description: (lopinavir (LPV) and ritonavir (RTV))
Study NCT02267109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z
Description: IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
Study NCT02267109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Booster-MVA-BN® Filo or saline placebo
Description: IM injection of Booster-MVA-BN® Filo or saline placebo
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1400 mg subcutaneously (SC), Day 1 Cycles 2-4
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV, Day 1 Cycles 1-4
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
Study NCT01724021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1400 mg SC, Day 1 Cycles 5-8
Study NCT00164515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized exercise programme (PEP)
Description: Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
Study NCT05850338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold pad pillow
Description: cold pad pillow application when women have vasomotor symptoms for 8 weeks
Study NCT05850338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: autogenic training
Description: Autogenic relaxation for three times a day for eight weeks
Study NCT01853605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomically shaped silicone gel-filled breast implants
Description: Surgical implant
Study NCT03249987 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: bladder diary
Description: electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
Study NCT02238860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacavir
Description: Entacavir-0.5 mg ,OD,for
Study NCT02238860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir ,300 mg,OD,for 48 weeks
Study NCT02272166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT02272166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study NCT04557046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal Swab
Description: Collection of one more nasal swabs
Study NCT02164305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening group
Description: Open-chain exercise for rotator cuff and scapular muscles
Study NCT02164305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular group
Description: Closed-chain exercise for shoulder muscles
Study NCT04557046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Collection of one more nasopharyngeal swabs
Study NCT04557046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Throat swab
Description: Collection of one more throat swabs
Study NCT04557046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fingerstick
Description: Collection of capillary blood from one or more fingersticks
Study NCT04557046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Saliva specimen
Description: Collection of free drool
Study NCT02903121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
Study NCT02903121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
Study NCT02903121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen (open label)
Description: Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
Study NCT02003287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VFSS
Description: Videofluoroscopic Swallow Study
Study NCT02003287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FEES
Description: Fiberoptic Endoscopic Swallow Study
Study NCT02791841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Reading Training
Description: RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.